Parabon NanoLabs, a subsidiary of Parabon Computation, a computing software provider,[3] was founded in 2008 by Steven Armentrout, Michael Norton and Christopher Dwyer. In 2018 Armentrout was the chief executive officer and President of Parabon Computation.[2][4][5] Parabon NanoLabs has developed oncology therapeutics and synthetic vaccines using nanotechnology and DNA phenotyping.[1]